224 related articles for article (PubMed ID: 26540491)
41. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
Caillaud D; Le Merre C; Martinat Y; Aguilaniu B; Pavia D
Int J Chron Obstruct Pulmon Dis; 2007; 2(4):559-65. PubMed ID: 18268929
[TBL] [Abstract][Full Text] [Related]
42. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial.
Vestbo J; Papi A; Corradi M; Blazhko V; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Singh D
Lancet; 2017 May; 389(10082):1919-1929. PubMed ID: 28385353
[TBL] [Abstract][Full Text] [Related]
43. Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.
Calverley PM; Anzueto AR; Dusser D; Mueller A; Metzdorf N; Wise RA
Int J Chron Obstruct Pulmon Dis; 2018; 13():1297-1308. PubMed ID: 29719385
[TBL] [Abstract][Full Text] [Related]
44. Consistent improvement in health-related quality of life with tiotropium in patients with chronic obstructive pulmonary disease: Novel and conventional responder analyses.
Tashkin DP; Bateman ED; Jones P; Zubek VB; Metzdorf N; Liu D; Leonard T; Clerisme-Beaty E; Wise RA
Respir Med; 2016 Nov; 120():91-100. PubMed ID: 27817821
[TBL] [Abstract][Full Text] [Related]
45. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
[TBL] [Abstract][Full Text] [Related]
46. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial.
Niewoehner DE; Rice K; Cote C; Paulson D; Cooper JA; Korducki L; Cassino C; Kesten S
Ann Intern Med; 2005 Sep; 143(5):317-26. PubMed ID: 16144890
[TBL] [Abstract][Full Text] [Related]
47. SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe.
Fležar M; Jahnz-Różyk K; Enache G; Martynenko T; Kristufek P; Škrinjarić-Cincar S; Kadlecová P; Martinovic G
Int J Chron Obstruct Pulmon Dis; 2013; 8():483-92. PubMed ID: 24159258
[TBL] [Abstract][Full Text] [Related]
48. Tiotropium Respimat Is Effective for the Treatment of Asthma at a Dose Lower Than That for Chronic Obstructive Pulmonary Disease.
Chin SJ; Durmowicz AG; Chowdhury BA
Ann Am Thorac Soc; 2016 Feb; 13(2):173-9. PubMed ID: 26650145
[TBL] [Abstract][Full Text] [Related]
49. Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO
Rabe KF; Chalmers JD; Miravitlles M; Kocks JWH; Tsiligianni I; de la Hoz A; Xue W; Singh D; Ferguson GT; Wedzicha J
Adv Ther; 2021 Jan; 38(1):579-593. PubMed ID: 33175291
[TBL] [Abstract][Full Text] [Related]
50. Triple therapy with salmeterol/fluticasone propionate 50/250 plus tiotropium bromide improve lung function versus individual treatments in moderate-to-severe Japanese COPD patients: a randomized controlled trial - Evaluation of Airway sGaw after treatment with tripLE.
Saito T; Takeda A; Hashimoto K; Kobayashi A; Hayamizu T; Hagan GW
Int J Chron Obstruct Pulmon Dis; 2015; 10():2393-404. PubMed ID: 26604737
[TBL] [Abstract][Full Text] [Related]
51. Effect of tiotropium on COPD exacerbations: A systematic review.
Halpin DM; Vogelmeier C; Pieper MP; Metzdorf N; Richard F; Anzueto A
Respir Med; 2016 May; 114():1-8. PubMed ID: 27109805
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of Tiotropium + Olodaterol in Patients with Chronic Obstructive Pulmonary Disease by Initial Disease Severity and Treatment Intensity: A Post Hoc Analysis.
Ferguson GT; Fležar M; Korn S; Korducki L; Grönke L; Abrahams R; Buhl R
Adv Ther; 2015 Jun; 32(6):523-36. PubMed ID: 26112656
[TBL] [Abstract][Full Text] [Related]
53. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease.
Keating GM
Drugs; 2012 Jan; 72(2):273-300. PubMed ID: 22217233
[TBL] [Abstract][Full Text] [Related]
54. Long-term safety of glycopyrrolate/eFlow
Ferguson GT; Goodin T; Tosiello R; Wheeler A; Kerwin E
Respir Med; 2017 Nov; 132():251-260. PubMed ID: 28919143
[TBL] [Abstract][Full Text] [Related]
55. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
56. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat
Steinmetz KO; Abenhardt B; Pabst S; Hänsel M; Kondla A; Bayer V; Buhl R
Int J Chron Obstruct Pulmon Dis; 2019; 14():1441-1453. PubMed ID: 31308649
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease.
Hohlfeld JM; Sharma A; van Noord JA; Cornelissen PJ; Derom E; Towse L; Peterkin V; Disse B
J Clin Pharmacol; 2014 Apr; 54(4):405-14. PubMed ID: 24165906
[TBL] [Abstract][Full Text] [Related]
58. Lung deposition of inhaled once-daily long-acting muscarinic antagonists
Crater GD; Johnson K; Ward J; Backer J
Ther Adv Respir Dis; 2022; 16():17534666221077561. PubMed ID: 35234085
[TBL] [Abstract][Full Text] [Related]
59. Tiotropium: an inhaled anticholinergic for chronic obstructive pulmonary disease.
Olin JL
Am J Health Syst Pharm; 2005 Jun; 62(12):1263-9. PubMed ID: 15947126
[TBL] [Abstract][Full Text] [Related]
60. Real-world effectiveness of early intervention with fixed-dose tiotropium/olodaterol vs tiotropium in Japanese patients with COPD: a high-dimensional propensity score-matched cohort analysis.
Muro S; Suzuki M; Nakamura S; Wang JR; Garry EM; Sakamoto W; de Souza S
Respir Res; 2021 Jun; 22(1):180. PubMed ID: 34140019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
